Shares of Balaji Amines Ltd surged to a record high on Thursday after the chemical manufacturer reported strong March quarter earnings. According to reports from Moneycontrol, Angel One, Trade Brains, and Business Today, the stock hit its 20 per cent upper circuit and rose to ₹1,622.55, marking its biggest single-day gain since April 2015 — the last time the stock had rallied 20 per cent in a single session. As of May 14, 2026, at 11:50 AM, the stock was trading at ₹1,623.40, up by 19.99% from the previous closing price of ₹1,352.15. The rally occurred as the broader BSE Sensex index posted a modest gain of 0.64%, highlighting the company-specific nature of the surge. The buying momentum came after the company reported its Q4FY26 numbers on Wednesday, after market hours.
The sharp move came after the company posted robust operating performance for the March quarter. As reported by Moneycontrol, Angel One, Trade Brains, and Business Today, total income rose 11.6% year-on-year to ₹402.52 crore, compared to ₹360.76 crore in the same quarter last year. Sequentially, the total income rose by 19.7% from ₹336.29 crore in the December 2025 quarter. Additionally, net profit jumped 60.2% year-on-year to ₹64.77 crore from ₹40.44 crore a year ago, with quarter-on-quarter growth of 110.6% from ₹30.76 crore in the December 2025 quarter. The company's board recommended a final dividend of ₹11 per equity share, representing 550% on the face value of ₹2 per share, demonstrating confidence in its financial position despite recent challenges. For the full fiscal year 2026, Balaji Amines recorded modest growth with total income increasing 1.6% to ₹1,453.79 crore and net profit improving 6.7% to ₹169.16 crore from the previous fiscal year. The company's earnings per share (EPS) for the quarterly period stood at ₹19.99, compared to ₹12.36 in the previous year's quarter.
EBITDA margins expanded sharply by 7 percentage points to 23.9%, compared with 16.9% in the year-ago period, reflecting improved operating efficiency and better product mix. According to Moneycontrol, this substantial improvement in operating efficiency was a main reason for the positive market reaction, with the margin expansion of 700 basis points directly boosting investor confidence. The company's improved operational leverage suggests potential stabilization in the aliphatic amines market, with the strong Q4 performance demonstrating the effectiveness of its operational improvements.
The strong performance of Balaji Amines was mirrored in the broader amines sector, with peer company Alkyl Amines also posting impressive gains. As reported by Moneycontrol, Alkyl Amines jumped 12% following the positive results from Balaji Amines, indicating broad-based optimism in the amines sector. This sector-wide rally highlights the positive sentiment surrounding the chemical manufacturing industry and the specific strength of companies operating in the amines space.
Balaji Amines is India's leading manufacturer of aliphatic amines, specialising in methylamines, ethylamines, derivatives of specialty chemicals, and pharma excipients. Incorporated in 1988 and headquartered in India, the company commenced commercial production of methyl amines in 1989 and has since systematically expanded its product portfolio and manufacturing capacity to serve a wide range of end-use industries. A key differentiator in the company's story is its indigenous technology development. Amine technology is a closely guarded process globally, with only a handful of companies possessing proprietary access. Balaji Amines was among the first in India to develop and commercialise an indigenously built amine technology platform, which it has refined over decades to deliver quality products at competitive costs. Today, the company's products are accepted in international markets and carry export quality status, with the company supplying to global majors across multiple geographies. The company has consistently expanded its manufacturing capacities and improved its processes to deliver high-quality products at competitive costs.
